EP Patent

EP3643702A1 — Prostaglandin derivatives

Assigned to Nicox SA · Expires 2020-04-29 · 6y expired

What this patent protects

Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

USPTO Abstract

Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Drugs covered by this patent

Patent Metadata

Patent number
EP3643702A1
Jurisdiction
EP
Classification
—
Expires
2020-04-29
Drug substance claim
No
Drug product claim
No
Assignee
Nicox SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.